Teleflex Incorporated (NYSE:TFX) – Analysts at KeyCorp dropped their Q4 2017 EPS estimates for Teleflex in a report released on Thursday, according to Zacks Investment Research. KeyCorp analyst M. Mishan now forecasts that the medical technology company will post earnings of $2.40 per share for the quarter, down from their previous estimate of $2.47. KeyCorp has a “Hold” rating on the stock.
Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $2.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.01 by $0.11. The business had revenue of $534.70 million during the quarter, compared to analyst estimates of $522.94 million. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The company’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.80 EPS.
ILLEGAL ACTIVITY NOTICE: “Teleflex Incorporated (NYSE:TFX) to Post Q4 2017 Earnings of $2.40 Per Share, KeyCorp Forecasts” was first reported by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://weekherald.com/2017/11/15/q4-2017-eps-estimates-for-teleflex-incorporated-tfx-cut-by-keycorp.html.
Other analysts also recently issued research reports about the stock. Deutsche Bank AG reaffirmed a “buy” rating and set a $238.00 price target (up previously from $220.00) on shares of Teleflex in a report on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and set a $253.00 price objective (up previously from $230.00) on shares of Teleflex in a research report on Wednesday, August 9th. Needham & Company LLC reaffirmed a “buy” rating on shares of Teleflex in a research note on Friday, August 4th. Zacks Investment Research raised shares of Teleflex from a “hold” rating to a “buy” rating and set a $233.00 target price for the company in a research note on Friday, August 25th. Finally, Stephens restated a “buy” rating and issued a $270.00 price objective (up from $230.00) on shares of Teleflex in a report on Monday, September 25th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. Teleflex has a consensus rating of “Hold” and an average target price of $274.44.
Shares of Teleflex (TFX) traded down $0.39 during mid-day trading on Monday, reaching $256.55. 261,600 shares of the company traded hands, compared to its average volume of 260,579. Teleflex has a one year low of $142.39 and a one year high of $263.97. The stock has a market cap of $11,574.96, a P/E ratio of 31.76, a price-to-earnings-growth ratio of 2.21 and a beta of 1.05. The company has a quick ratio of 3.70, a current ratio of 4.72 and a debt-to-equity ratio of 0.88.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Wednesday, November 15th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date of this dividend is Tuesday, November 14th. Teleflex’s dividend payout ratio (DPR) is 24.82%.
In related news, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $211.75, for a total transaction of $42,350.00. Following the completion of the transaction, the director now directly owns 8,080 shares in the company, valued at approximately $1,710,940. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 600 shares of company stock valued at $138,162 over the last 90 days. 2.39% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Neuberger Berman Group LLC increased its position in Teleflex by 0.5% during the second quarter. Neuberger Berman Group LLC now owns 5,708 shares of the medical technology company’s stock worth $1,186,000 after buying an additional 28 shares during the period. Stifel Financial Corp grew its stake in shares of Teleflex by 0.6% in the 2nd quarter. Stifel Financial Corp now owns 5,399 shares of the medical technology company’s stock valued at $1,121,000 after purchasing an additional 31 shares during the last quarter. Toronto Dominion Bank grew its stake in shares of Teleflex by 14.5% in the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 70 shares during the last quarter. Xact Kapitalforvaltning AB grew its stake in shares of Teleflex by 2.7% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 3,482 shares of the medical technology company’s stock valued at $723,000 after purchasing an additional 90 shares during the last quarter. Finally, World Asset Management Inc boosted its stake in shares of Teleflex by 3.6% in the second quarter. World Asset Management Inc now owns 2,942 shares of the medical technology company’s stock valued at $611,000 after buying an additional 101 shares in the last quarter. 90.45% of the stock is currently owned by institutional investors.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.